Immune-Mediated Neuropathies

Research output: Contribution to journalReview article

Purpose of review: The purpose of this review article is to discuss the pathogenesis of acute and chronic immune-mediated neuropathies along with the recent advances in their treatment. Recent findings: Since the first description of Guillain-Barre syndrome (GBS) more than a century ago, there have been numerous forms of immune-mediated neuropathies described expanding the spectrum. Understanding the role of the immune system in the pathogenesis of immune-mediated neuropathies has been an advancement towards the diagnosis and treatment. Summary: It is postulated that immune-mediated neuropathies are a group of diseases resulting from autoimmunity towards multiple components of peripheral nervous system. These have a wide range of pathologic mechanisms, defined clinical presentations, electro-diagnostic and laboratory findings which help in diagnosis and management. Although immunosuppression is the common modality of treatment for these disorders, uncovering distinct pathogenic mechanisms can allow for targeted immunomodulation.

Original languageEnglish (US)
Article number28
JournalCurrent Treatment Options in Neurology
Volume21
Issue number6
DOIs
StatePublished - Jun 1 2019

Altmetrics

Cite this

Standard

Immune-Mediated Neuropathies. / Fadia, Mithila; Shroff, Sheetal; Greene, Ericka P.

In: Current Treatment Options in Neurology, Vol. 21, No. 6, 28, 01.06.2019.

Research output: Contribution to journalReview article

Harvard

Fadia, M, Shroff, S & Greene, EP 2019, 'Immune-Mediated Neuropathies' Current Treatment Options in Neurology, vol. 21, no. 6, 28. https://doi.org/10.1007/s11940-019-0569-y

APA

Fadia, M., Shroff, S., & Greene, E. P. (2019). Immune-Mediated Neuropathies. Current Treatment Options in Neurology, 21(6), [28]. https://doi.org/10.1007/s11940-019-0569-y

Vancouver

Fadia M, Shroff S, Greene EP. Immune-Mediated Neuropathies. Current Treatment Options in Neurology. 2019 Jun 1;21(6). 28. https://doi.org/10.1007/s11940-019-0569-y

Author

Fadia, Mithila ; Shroff, Sheetal ; Greene, Ericka P. / Immune-Mediated Neuropathies. In: Current Treatment Options in Neurology. 2019 ; Vol. 21, No. 6.

BibTeX

@article{1592ef55c6984ed18a724821462c68e4,
title = "Immune-Mediated Neuropathies",
abstract = "Purpose of review: The purpose of this review article is to discuss the pathogenesis of acute and chronic immune-mediated neuropathies along with the recent advances in their treatment. Recent findings: Since the first description of Guillain-Barre syndrome (GBS) more than a century ago, there have been numerous forms of immune-mediated neuropathies described expanding the spectrum. Understanding the role of the immune system in the pathogenesis of immune-mediated neuropathies has been an advancement towards the diagnosis and treatment. Summary: It is postulated that immune-mediated neuropathies are a group of diseases resulting from autoimmunity towards multiple components of peripheral nervous system. These have a wide range of pathologic mechanisms, defined clinical presentations, electro-diagnostic and laboratory findings which help in diagnosis and management. Although immunosuppression is the common modality of treatment for these disorders, uncovering distinct pathogenic mechanisms can allow for targeted immunomodulation.",
keywords = "AIDP, CIDP, Cancer-related neuropathy, IVIg, Immune neuropathy treatment, MMN",
author = "Mithila Fadia and Sheetal Shroff and Greene, {Ericka P.}",
year = "2019",
month = "6",
day = "1",
doi = "10.1007/s11940-019-0569-y",
language = "English (US)",
volume = "21",
journal = "Current Treatment Options in Neurology",
issn = "1092-8480",
publisher = "Current Science, Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Immune-Mediated Neuropathies

AU - Fadia, Mithila

AU - Shroff, Sheetal

AU - Greene, Ericka P.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Purpose of review: The purpose of this review article is to discuss the pathogenesis of acute and chronic immune-mediated neuropathies along with the recent advances in their treatment. Recent findings: Since the first description of Guillain-Barre syndrome (GBS) more than a century ago, there have been numerous forms of immune-mediated neuropathies described expanding the spectrum. Understanding the role of the immune system in the pathogenesis of immune-mediated neuropathies has been an advancement towards the diagnosis and treatment. Summary: It is postulated that immune-mediated neuropathies are a group of diseases resulting from autoimmunity towards multiple components of peripheral nervous system. These have a wide range of pathologic mechanisms, defined clinical presentations, electro-diagnostic and laboratory findings which help in diagnosis and management. Although immunosuppression is the common modality of treatment for these disorders, uncovering distinct pathogenic mechanisms can allow for targeted immunomodulation.

AB - Purpose of review: The purpose of this review article is to discuss the pathogenesis of acute and chronic immune-mediated neuropathies along with the recent advances in their treatment. Recent findings: Since the first description of Guillain-Barre syndrome (GBS) more than a century ago, there have been numerous forms of immune-mediated neuropathies described expanding the spectrum. Understanding the role of the immune system in the pathogenesis of immune-mediated neuropathies has been an advancement towards the diagnosis and treatment. Summary: It is postulated that immune-mediated neuropathies are a group of diseases resulting from autoimmunity towards multiple components of peripheral nervous system. These have a wide range of pathologic mechanisms, defined clinical presentations, electro-diagnostic and laboratory findings which help in diagnosis and management. Although immunosuppression is the common modality of treatment for these disorders, uncovering distinct pathogenic mechanisms can allow for targeted immunomodulation.

KW - AIDP

KW - CIDP

KW - Cancer-related neuropathy

KW - IVIg

KW - Immune neuropathy treatment

KW - MMN

UR - http://www.scopus.com/inward/record.url?scp=85067648907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067648907&partnerID=8YFLogxK

U2 - 10.1007/s11940-019-0569-y

DO - 10.1007/s11940-019-0569-y

M3 - Review article

VL - 21

JO - Current Treatment Options in Neurology

T2 - Current Treatment Options in Neurology

JF - Current Treatment Options in Neurology

SN - 1092-8480

IS - 6

M1 - 28

ER -

ID: 50471927